Bearish Chart Formation for Interpace Diagnostics Group, Inc. (IDXG) After Forming Bearish Wedge Down Chart Pattern

July 13, 2018 - By Benjamin Allen

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Logo

The stock of Interpace Diagnostics Group, Inc. (IDXG) formed a down wedge with $0.88 target or 6.00 % below today’s $0.94 share price. The 7 months wedge indicates high risk for the $26.16M company. If the $0.88 price target is reached, the company will be worth $1.57 million less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock increased 1.71% or $0.015769 during the last trading session, reaching $0.938769. About 259,848 shares traded. Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) has declined 55.08% since July 13, 2017 and is downtrending. It has underperformed by 67.65% the S&P500.

Analysts await Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) to report earnings on August, 9. They expect $-0.08 EPS, up 87.69 % or $0.57 from last year’s $-0.65 per share. After $-0.11 actual EPS reported by Interpace Diagnostics Group, Inc. for the previous quarter, Wall Street now forecasts -27.27 % EPS growth.

More news for Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) were recently published by:, which released: “Ladenburg Thalmann Starts Interpace Diagnostics Group Inc (IDXG ) at Buy” on June 22, 2018.‘s article titled: “Benzinga’s Top Upgrades, Downgrades For June 22, 2018” and published on June 22, 2018 is yet another important article.

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. The company has market cap of $26.16 million. The firm offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its proprietary PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. It currently has negative earnings. The Company’s clients consist primarily of physicians, hospitals, and clinics.

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.